• Small Molecules
    • Services
      • Drug Substance (API)
      • Particle Engineering
      • Drug Product
    • Technologies
      • Highly Potent API (HPAPI)
      • ADCs
      • Spray Dried Dispersions
      • Micronization & Jet Milling
      • Inhaled Delivery (DPI)
    • Solutions
      • Early Phase API
      • Commercial Production API
      • Bioavailability Enhancement
      • Integrated Offerings
    • Knowledge Center
      • Webinars
      • Presentations
      • Publications
      • Meet the Experts
      • View all
    View all Small Molecules offerings
    View all locations
    Clinical drug development & preformulation

    Knowledge Center

    View all the latest resources


    Visit our Knowledge Center

  • Biologics
    • Modalities
      • Mammalian
      • Microbial
      • ADCs / Bioconjugates
      • mRNA / LNP
      • Drug Product
    • Technologies & Products
      • Expression Technologies
      • Discovery Products
      • Bioprocessing Products
    • Discovery and Preclinical
      • Early De-risking & Optimization
      • Cell Line & Strain Development
      • Process Development & Optimization
      • Analytical Development
      • Formulation Development
      • Non-GMP Manufacture
    • Clinical and Commercial
      • Process Development & Optimization
      • Formulation Optimization
      • cGMP Drug Substance Manufacture
      • cGMP Drug Product Manufacture
    Technical Support
    Regulatory Support
    View all locations
    View all Biologics offerings
    Woman and microscope

    Knowledge Center

    View all the latest resources available on site


    Visit our Knowledge Center

  • Cell & Gene
    • Services
      • Process Development
      • cGMP Manufacturing
      • Regulatory Consulting
      • Bioassay Services
      • Tissue Acquisition
    • By Modality
      • Autologous
      • Allogeneic
      • Viral Vectors
      • iPSCs
      • Exosomes
    • Technologies
      • MODA® Platform
      • Cocoon® Platform
      • Nucleofector® Technology
      • TheraPEAK® Media
      • Endotoxin and Pyrogen Testing
    • Knowledge Center
      • Webinars
      • Articles
      • Whitepapers & Publications
      • eBooks
      • Presentations
      • View all
    View all Cell & Gene offerings
    View all Bioscience Products
    View all locations
  • Capsules & Health Ingredients
    • Health Ingredients
    • Nutraceutical capsules
    • Pharmaceutical capsules
    • Capsule filling equipment
  • Contact
Small Molecules
Small Molecules
Services
  • Drug Substance (API)
  • Particle Engineering
  • Drug Product
Technologies
  • Highly Potent API (HPAPI)
  • ADCs
  • Spray Dried Dispersions
  • Micronization & Jet Milling
  • Inhaled Delivery (DPI)
Solutions
  • Early Phase API
  • Commercial Production API
  • Bioavailability Enhancement
  • Integrated Offerings
Knowledge Center
  • Webinars
  • Presentations
  • Publications
  • Meet the Experts
  • View all
Back
Biologics
Biologics
Modalities
  • Mammalian
  • Microbial
  • ADCs / Bioconjugates
  • mRNA / LNP
  • Drug Product
Technologies & Products
  • Expression Technologies
  • Discovery Products
  • Bioprocessing Products
Discovery and Preclinical
  • Early De-risking & Optimization
  • Cell Line & Strain Development
  • Process Development & Optimization
  • Analytical Development
  • Formulation Development
  • Non-GMP Manufacture
Clinical and Commercial
  • Process Development & Optimization
  • Formulation Optimization
  • cGMP Drug Substance Manufacture
  • cGMP Drug Product Manufacture
Back
Cell & Gene
Cell & Gene
Services
  • Process Development
  • cGMP Manufacturing
  • Regulatory Consulting
  • Bioassay Services
  • Tissue Acquisition
By Modality
  • Autologous
  • Allogeneic
  • Viral Vectors
  • iPSCs
  • Exosomes
Technologies
  • MODA® Platform
  • Cocoon® Platform
  • Nucleofector® Technology
  • TheraPEAK® Media
  • Endotoxin and Pyrogen Testing
Knowledge Center
  • Webinars
  • Articles
  • Whitepapers & Publications
  • eBooks
  • Presentations
  • View all
Back
Capsules & Health Ingredients
Capsules & Health Ingredients
Health Ingredients
Nutraceutical capsules
Pharmaceutical capsules
Capsule filling equipment
Back
Contact
Back
  • Home
  • Biologics
  • Mammalian Biopharmaceutical Services
  • Mammalian Process Development

Mammalian Process Development and Optimization

Benefit from access a full range of services to develop upstream and downstream processes that meet your needs. We develop processes for cell lines developed with our GS Expression System® and those brought to us by our customers.
Find out how Lonza can help
35+ years' experience in developing processes for cGMP manufacturing.
15+ biological full BLA / MAA supported in the last 5 years.
500+ customer processes transferred into cGMP manufacturing since 2001.

A proven track record in mammalian cell culture

We provide robust and scalable processes for manufacture of biopharmaceuticals for clinical and commercial supply.

Our development teams work closely with the manufacturing and quality assurance groups to define and document all new processes and to create robust manufacturing procedures. We perform a complete development program or individual work packages based on our customers' technology. Our services are flexible and are created through close partnerships with our customers throughout the lifecycle of their product.

Since 2001, we have transferred more than 500 customer processes into cGMP manufacturing for small, mid or large scale at all product lifecycle stages.

For the last 30 years our GS Gene Expression System® has been continuously improved for robust technical performance and is able to express a diverse range of biopharmaceuticals with high titers. The system is used within Lonza and is also available for out-license.

tech working in lab with computer 

Tailorable technical scope and timelines when necessary to meet customers' needs

When you bring a non-Lonza cell line to us and you want us to evaluate our platform cell culture process, a typical initial process development study includes the assessment of inoculum expansion and production bioreactor processes, feeding strategies and cell line stability studies. This rapid evaluation will test if the platform is suitable for the cell line and product. If it is not, we use our expertise to adapt our platform process to improve productivity or match a specific product characteristic.

We have transferred-in processes for a variety of expression systems and cell lines. The activities we undertake are driven by customer needs and they can range from ensuring fit to our manufacturing plant to optimization to improve product quality or productivity and on-to scale-up before being transferred into our manufacturing network.

Cell Iine process development 

Get a robust and reproducible platform manufacturing process

Our platform manufacturing process is robust and reproducible, with scalability proven up to 20 kL. Our well-characterized platform process offers many benefits to you:

  • Accelerated timelines. Because our cell lines are selected to fit our platform process, this leads to higher success and lower error rates.
  • Simpler troubleshooting. If excursions occur, troubleshooting and if needed, modifying a platform process containing our proprietary culture media and feeds is easier than for a customized one.
  • 35+ years' experience in developing processes for cGMP manufacturing enables us to support you to optimize your existing process for commercial manufacturing.
  • Quick identification for critical process parameters to speed up process characterization and validation activities.
Process development 

Broad experience with regulatory agencies across the globe and process validation in mammalian systems

Over the past 5 years, we have provided the complete CMC documentation for more than 15 biological full BLA / MAA, including products with Breakthrough or PRIME designation. We develop open and trusted communication channels with our customers, so that we can support them when they have to respond to the authorities’ questions.

The CMC section of a successful BLA application requires good planning, good science and a thorough understanding of the process and product profile. We take a structured approach to developing a tailored program for each product and process that considers all CMC aspects of a BLA program.

We have developed a strategy that supports products with accelerated approval pathways. The scope of the studies performed is dependent on your needs and the current regulatory guidelines.

filing worker 

Related Offerings

Ibex® Design | Standard mAbs DNA-to-IND Program
Benefit from our fixed price, fastest DNA-to-IND program that minimizes risk and uncertainty from...
Learn More
Bispecific Antibodies DNA-to-IND Program
We provide an integrated drug substance/drug product DNA to IND program with reliable timelines...
Learn More
Fabs, Fusion, Scaffold and Other Recombinant Proteins DNA-to-IND Program
We will screen more clones to find the highest titer clone. The offering is suitable for customers...
Learn More
Mammalian Cell Line Development
Benefit from our flexible approach to cell line development matching your project’s priorities in...
Learn More
Mammalian Analytical Development
We provide analytical capabilities encompassing a wide range of technologies to support all stages...
Learn More
Mammalian Drug Substance Manufacturing
Our global biopharmaceutical mammalian manufacturing network offers a range of cGMP production...
Learn More
Parenteral drug product formulation development
We offer formulation development for all biologics modalities and dosage forms. Learn more.
Learn More
Drug Product Manufacture
We offer fully integrated biologics manufacturing services from selection and qualification of the...
Learn More
Biologics Regulatory Services
Partner with our dedicated biologics regulatory team to define the optimal regulatory strategy for...
Learn More
Biologics

Related Insights

Knowledge Center
Presentation (on-demand)
CMC Strategy to take Bispecifics from DNA to IND in 13 Months
Lonza has applied it's 35 years of CMC experience in Biologics to develop an end-to-end...
Presentation (on-demand)
Embrace Molecule Complexity with Optimized Expression Technologies
Biologic drugs are increasingly complex, creating numerous challenges for biopharmaceutical...
Article
Small Biotech Success - Corvus
William B. Jones, Senior Vice President of Pharmaceutical Development at Corvus Pharmaceuticals,...
Knowledge Center

Latest news

View all Articles
31 Jan 2023
Media Advisory
Lonza Celebrates Groundbreaking of New Commercial Drug Product Facility in Stein
View Article
31 Jan 2023
Media Advisory
Lonza Celebrates Groundbreaking of New Commercial Drug Product Facility in Stein
View Article
30 Jan 2023
Media Advisory
Lonza Expands Manufacturing Collaboration With Asher Biotherapeutics to Include AB248, a...
View Article
30 Jan 2023
Media Advisory
Lonza Expands Manufacturing Collaboration With Asher Biotherapeutics to Include AB248, a...
View Article
17 Jan 2023
Media Advisory
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
View Article
17 Jan 2023
Media Advisory
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
View Article
9 Jan 2023
Media Advisory
Lonza and Context Therapeutics Enter Manufacturing Agreement for Bispecific Antibody Targeting...
View Article
9 Jan 2023
Media Advisory
Lonza and Context Therapeutics Enter Manufacturing Agreement for Bispecific Antibody Targeting...
View Article
View all Articles
Ways to Contact
  • Contact Us
  • Regulatory Support
  • Locations
  • Partnering with Us
Resources
  • Knowledge Center
  • Meet the Experts
  • Upcoming Events
Terms & Conditions
  • Terms and Conditions
  • Legal Disclaimer
  • Privacy Policy
  • California CCPA Notice
  • Transparency in Coverage
Lonza.com
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
  • Sitemap
© 2023 Lonza. All rights reserved.